Cost-effectiveness analysis of penpulimab plus carboplatin-paclitaxel as first-line treatment for metastatic squamous non-small-cell lung cancer in China
From the perspective of the Chinese healthcare system, penpulimab combined with first-line chemotherapy demonstrates is cost-effective at a willingness-to-pay threshold of $38,060.00 per QALY for patients with metastatic sqNSCLC and represents a promising first-line treatment option.
Authors
- Luwei Wang (ORCID: https://orcid.org/0009-0001-0256-0795)
- Jiasheng Chen (ORCID: https://orcid.org/0000-0003-2819-1761)
- Lihui Lin (ORCID: https://orcid.org/0009-0003-6041-9452)
- Xiaowei Huang (ORCID: https://orcid.org/0000-0002-3120-540X)
Institutions
- Fujian Medical University (CN)
- Zhangzhou Municipal Hospital of Fujian Province (CN)
- Children’s Hospital of Fudan University Xiamen Branch (CN)
- Xiamen Maternal and Child Health Hospital (CN)
Publication Details
- Journal
- Health Economics Review
- Published
- 2025-07-12
- DOI
- https://doi.org/10.1186/s13561-025-00656-1
- Citations
- 2
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 3.04
Funders
- Xiamen Municipal Bureau of Science and Technology
- Natural Science Foundation of Fujian Province